ArriVent BioPharma, Inc. Common Stock
ArriVent BioPharma, Inc. Common Stock (AVBP) Stock Forecast & Analyst Price Target
Wall Street consensus, 12-month price targets, model projections, and EPS/revenue estimates — from analyst data and price history.
avbp · stock forecast · 7 analysts (3M) · FMP · updated Jun 8, 2026
Analyst Rating & Consensus
Based on 7 Wall Street analysts in the past 3 months
Buy
7 analysts
consensus
Rating Breakdown
12-Month Price Target
High
$45.00
Consensus
$45.00
+47.4% upside
Low
$45.00
Median: $45 · Last Close: $30.53
12-Month Price Target Forecast
Historical closing prices + analyst 12-month price target forecast cone
Short-Term Price Prediction
BullAlgorithmically generated · Updated daily
| Date | Predicted Price | Change |
|---|---|---|
| 2026-06-09 | $32.05 | ↑ 5.00% |
1-day model range: $31.82–$32.29. Peak: $32.29 (+5.00%).
Long-Term Stock Price Prediction
Annual stock price forecast · 2027 / 2028 / 2029 / 2030 / 2031
| Year | Avg Price | Change |
|---|---|---|
| 2027 | $35 | +15.3% |
| 2028 | $38 | +24.9% |
| 2029 | $40 | +30.7% |
| 2030 | $41 | +34.0% |
| 2031 | — | +35.9% |
Stock Forecast Based on Technical Analysis
14 TA signals (SMA×6 + EMA×6 + RSI + MACD) · EEAT method transparency
Market Sentiment
BULLISH
Based on 14 technical indicators
Refreshes daily from EOD close
Moving Averages · AVBP · Jun 8, 2026
Latest Analyst Ratings & Upgrades
| Date | Brokerage | Action | Rating |
|---|---|---|---|
| 2026-05-29 | Truist Securities | Maintains | Buy→Buy |
| 2026-05-13 | Citigroup | Maintains | Buy→Buy |
| 2026-04-24 | Citigroup | Maintains | Buy→Buy |
| 2026-03-23 | B. Riley Securities | Maintains | Buy→Buy |
| 2026-03-06 | Oppenheimer | Maintains | Outperform→Outperform |
| 2026-03-06 | HC Wainwright & Co. | Maintains | Buy→Buy |
| 2026-03-06 | Citigroup | Maintains | Buy→Buy |
| 2025-11-11 | Citigroup | Maintains | Buy→Buy |
| 2025-08-12 | HC Wainwright & Co. | Maintains | Buy→Buy |
| 2025-08-12 | Citigroup | Maintains | Buy→Buy |
Wall Street analysts have recently issued updated ratings on ArriVent BioPharma, Inc. Common Stock (AVBP) stock. Of the recent 25 rating actions, 0 were upgrades and 0 were downgrades. 7 analysts currently cover AVBP.
Analyst Recommendation Trends
AVBP analyst recommendation trends show increasing buy-side sentiment over the past 6 months. Buy rating actions changed from 1 to 2 per month.
Financial Forecast: EPS & Revenue Estimates
Revenue This Year
$0M
↓ 99.9% YoY
Revenue Next Year
$44M
↑ 34804.7% YoY
EPS This Year
$-4.00
EPS Next Year
$-3.42
↓ 14.5% YoY
EPS ForecastReported vs Estimated
Analysts forecast AVBP EPS of $-4.00 for the current fiscal year, based on estimates from 8 analysts. The AVBP revenue forecast is $0M for the current year. These are analyst consensus estimates via FMP / S&P Global.
About Forecast & Price Prediction
The AVBP stock forecast is supported by two independent data sources: analyst consensus ratings from 7 Wall Street analysts (S&P Global / FMP), and technical analysis calculated from historical EOD price data. The consensus AVBP price target is $45.00 (+47.4% upside), with an analyst consensus of Buy.
The AVBP short-term stock prediction for tomorrow is $32.05 (+5.00%). The AVBP stock price prediction for 2027 estimates an average of $35. The AVBP stock prediction for 2030 projects a range of $38–$44.
ArriVent BioPharma, Inc. Common Stock trades on NASDAQ under the ticker AVBP. The AVBP stock outlook for 2027 is broadly positive, supported by a Buy consensus among 100% of covering analysts.
Frequently asked questions
AVBP forecast · 8 questionsAccording to 7 Wall Street analysts, the average 12-month AVBP price target is $45.00, with a high forecast of $45.00 and a low of $45.00. The median price target is shown in the chart above when available. This implies +47.4% potential upside from the current price of $30.53.
· Analyst data: Financial Modeling Prep (FMP) · S&P Global Market Intelligence · Technical analysis: FMP /historical-price-eod/light · Updated: Hourly (analyst) · Daily (technical)
⚠ This information is provided for informational purposes only and does not constitute investment advice. Short-term and long-term price predictions are algorithmically generated and carry significant uncertainty. Past performance does not guarantee future results. Always conduct your own due diligence before making investment decisions.